First results from the ACP-001 study presented at EHA

Today results from the first-in-human study ACP-001 was made public at the 2020 EHA meeting. 

Key findings from the study:

  • Overall survival (OS) 100% after a median follow-up time of 60 months 
  • Median progression free survival (PFS) 34 months
  • No serious adverse events

The present study demonstrates that autologous NK cell-based immunotherapy is feasible and demonstrates clinical applicability with efficacy responses in an upfront autologous HSCT-setting in multiple myeloma (MM). The treatment strategy opens for usage of autologous NK cells in clinical settings where patients are not readily eligible for allogeneic NK cell-based treatments, including MRD and maintenance treatment in MM and other forms of malignancies.

XNK Therapeutics names new CEO

Johan Liwing, from Janssen (Johnson & Johnson), has been appointed new acting CEO at XNK Therapeutics. He is succeeding the former CEO Karin Mellström whom will retire, but remain disposable for the the company as Project Manager. Johan Liwing has over 15 year’s of experience from leading positions within the Life science industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson), he has held various positions in health economics, sales & marketing, as well as observational research. In his most recent position at Janssen, as global senior director, he was responsible for the development and use of observational data.

XNK Therapeutics joins the NextGenNK consortium

NextGenNK is a Competence Center founded by Sweden’s Innovation Agency. It was launched in January 2020, for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. XNK Therapeutics is one of the founding partners of the Competence Center. The collaboration will extend for a period of five years.